Tag:

Mylan

Latest Headlines

Latest Headlines

Mylan didn't disclose director's ties to HQ land deal: WSJ

Back in late 2013, Mylan moved into a new headquarters in an office park near Pittsburgh--a 5-story building for about 700 employees.

UPDATED: You want a formal offer, Mylan? Teva could have one this week

Last month, Mylan Chairman Robert Coury challenged suitor Teva to either put up a formal bid or step aside and let his company proceed with its plan to pursue its own target, Perrigo. And he may be getting what he asked for.

Will Mylan boost its Perrigo bid? New securities filing suggests it won't

Perrigo was none too fond of Mylan's most recent offer when it made it back in April. Yet it looks like that's the one Mylan's sticking with--at least for now.

Mylan CFO jetting off to Israel for stock exchange meeting: Reuters

Mylan is sending its CFO, John Sheehan, on the road in Israel.

Teva ratchets up its M&A pressure on Mylan with larger stake

Teva has upped its Mylan stake yet again--this time, passing a critical threshold that could help it pose a legal challenge to its generics rival.

It's Teva vs. Momenta/Sandoz for Copaxone patients, with Mylan's version MIA

On Thursday, Momenta and Novartis' Sandoz launched their copy of Teva blockbuster Copaxone after a U.S. court nixed the multiple sclerosis drug's patent for the second time. Industry watchers largely expected the move, Bernstein's Ronny Gal wrote in a note to clients. The real question? When Mylan will enter the market with its own copy.

Teva turns up the heat on Mylan, taking its stake past critical threshold

Teva has upped its Mylan stake yet again--this time, passing a critical threshold that could help it pose a legal challenge to its generics rival.

Mylan's Bangalore unit cancer drug recall expanded as firm works M&A angles

Mylan has filled out details on an expanded recall of two drugs manufactured by Bangalore-based Agila Onco, which it bought from Strides Arcolab two years ago, as the company works to fend off a takeover offer from Teva Pharmaceuticals, while moving on its own unsolicited bid for Perrigo.

Big Mylan shareholder Abbott backs Mylan's Perrigo buy

Mylan can breathe a little easier knowing it has support from its largest shareholder in its quest to pick up Perrigo. After all, it's not just a big buyout at stake--but the opportunity to thwart its own unwanted takeover by generics rival Teva.

Pulmatrix hits Wall Street with $10M and a Mylan deal

Respiratory biotech Pulmatrix has completed its nontraditional path to the public markets, closing a merger with upstart Ruthigen to inherit a Nasdaq listing, at the same time banking $10 million and partnering up with generics giant Mylan.